2022-RA-1093-ESGO Validation of self-sampling use for a multiplexed biomarker assay for HPV and dysplasia detection. (20th October 2022)

• Record Type: Journal Article
• Authors: Skof, Anna Sophie; Payrich, Eva-Maria; Struck, Maja; Thies, Sarah; Schreckenberger, Carola; Sehouli, Jalid; Kaufmann, Andreas M
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A411
• Page End: A411
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.881
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The use of self-sampling in cervical cancer (CxCa) screening increases the number of participants and enables the inclusion of prior underscreened women in rural areas. For PCR and DNA-based testing self-sampling is as sensitive as physician-sampling. We compared self- and physician-sampling for analysis by QuantiGene-Molecular-Profiling-Histology assay (QG-MPH) to detect and grade cervical dysplasia in a triage setting. Methodology: Women with an equivocal screening result were recruited and a cervical sample (Cervex broom) was taken into ThinPrep/PreservCyt. Participants were asked to take a self-sample (Evalyn-Brush) and fill a questionnaire. Crude lysates were used for the QG-MPH assay. This multiplexed Luminex bead-based technology platform (QuantiGene 2.0) detects and quantifies the mRNA abundance of 18 Human Papillomavirus (HPV) genotype-specific oncogenes, reference genes and cellular biomarkers characterizing dysplasia stages, simultaneously. Formerly developed biomarker-based risk scores predict CIN2+, CIN3+, or CxCa. Results: Of 699 study participants, 601 performed self-sampling (85.9%). Invalid samples in QG-MPH was comparable between self- and physician-sampling with 16.1% and 14.9%, respectively. Of 132 histologically confirmed CIN3 lesions QG-MPH determined in the physician-taken sample 61.4% (n=81) as CIN3 or higher, 25.8% (n=34) as low-grade lesions, and 12.9% (n=17) were not evaluable. Of 109 self-samplers from CIN3 positive women QG-MPH determined 17.4% (n=19) as CIN3 or higher, 59.6% (n=65) as low-grade and 22.9% (n=25) were not evaluable. PCR-based HPV testing detected 78.2% of physician- and 74.9% of self-samples positive while QG-MPH 52.5% (n=315) and 32.3% (n=194), respectively. Concordance was 82.0% by PCR and 63.8% by QG-MPH. Conclusion: While cellularity of self-taken samples is sufficient for valid measurement by QG-MPH, less high-grade lesions and HPV-infections are detected. Optimization of cutoffs for the self-taken sample may improve the sensitivity. We hypothesize that 'missed' CIN3 by QG-MPH biomarker profiling may be non-progressor lesions. This will be investigated further.